How to Place a Medical Device on the Mexican Market in 2026: Registro Sanitario versus 2010 FDA/Canada and 2012 Japan Equivalence Agreements versus Option F Abbreviated Pathway under the 18 July 2025 Lineamientos, IMDRF Management Committee versus MDSAP for GMP Certificates Only, Homoclave COFEPRIS-04-050 Still Physical, the 20 August 2026 Visor, Official LFD Article 195-A Fees, and Why CE / 510(k) / NMPA / MDSAP Do Not Replace a Mexican Sanitary Registration

International medical device distributors, private-label procurement directors, and regulatory affairs executives evaluating sterile single-use surgical consumables from overseas manufacturing hubs repeatedly encounter commercial narratives that reduce Mexican market access to a simple formality. Export managers and local brokers often claim that holding an active European Union CE Certificate under Regulation (EU) 2017/745 (MDR), a United States FDA 510(k) clearance, a China National Medical Products Administration (NMPA) certificate, or an audit certificate under the Medical Device Single Audit Program (MDSAP) guarantees immediate Mexican customs clearance. In other instances, buyers are told that Mexico abolished all previous bilateral fast-track routes in July 2025, that regulatory applications can be filed paperlessly via a web portal or delivered on a USB drive, or that searching the public portal launched by the Federal Commission for the Protection against Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS) on 20 August 2026 replaces the need for a physical registration certificate.

Every one of those assertions misinterprets the Mexican administrative and statutory framework. Under the Mexican Constitution (Article 4) and the statutory mandates of the Ley General de Salud (LGS) and the Reglamento de Insumos para la Salud (RIS), foreign marketing authorizations do not replace Mexican sanitary approvals⁸. While international clearances serve as indispensable evidentiary inputs to qualify for expedited or abbreviated evaluation, every non-exempt medical device distributed in Mexico must obtain a formal Sanitary Registration (Registro Sanitario) issued directly by COFEPRIS to an authorized Mexican entity (Titular del Registro Sanitario)¹.

This operational regulatory guide establishes the legally binding framework governing medical device market placement in Mexico in 2026. It decodes the coexistence of the three active fast-track instruments—the 2010 FDA/Health Canada agreement, the 2012 Japan agreement, and the 18 July 2025 Option F Abbreviated Regulatory Pathway (Lineamientos generales para la aplicación de la vía regulatoria abreviada)—demonstrating why Transitory Article Fifth did not repeal the device agreements. Furthermore, it audits the precise scope of Article 24 (clarifying that MDSAP is recognized exclusively for Good Manufacturing Practice verification rather than product clearance), details the physical dossier lodgement requirements for homoclave COFEPRIS-04-050, analyzes official user fees under Ley Federal de Derechos Article 195-A-III, and evaluates the legal limitations of the 20 August 2026 digital registry viewer.

Table of Contents

• Does a CE mark, 510(k), NMPA certificate, MDSAP audit or WHO prequalification replace a COFEPRIS registro sanitario?
• Which three instruments are actually live in 2026: 2010 FDA/Canada, 2012 Japan, and 18 July 2025 Option F — and did Transitory Fifth repeal the device agreements?
• What does Article 24 actually recognize: IMDRF Management Committee country decisions versus MDSAP full members for GMP certificates only?
• Who may apply — overseas manufacturer, Mexican titular, or consultancy 'MRH' — and what must already exist in Mexico?
• How does Mexico classify devices I-II-III under RIS Article 83, and why must you not import EU IIa, NMPA Class II or FDA product-code class as the Mexican class?
• What do Ley Federal de Derechos Article 195-A-III and Article 38 print for fees and the abbreviated clock, versus RIS standard 30/35/60-day clocks and consultancy USD/10-year cards?
• Can homoclave COFEPRIS-04-050 be filed digitally, and why does a USB stick not replace the physical expediente?
• What the 20 August 2026 visor can and cannot prove when you try to verify a listing
• Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber versus Class I aftercare pants, and why NOVACURE is out of scope
• Distributor checklist, apostille/CLV pack, red flags, and the documents to request before the first Mexican shipment
• Where VEMERIX fits — and where due diligence still begins
• Frequently Asked Questions

Does a CE mark, 510(k), NMPA certificate, MDSAP audit or WHO prequalification replace a COFEPRIS registro sanitario?

The constitutional and statutory foundation of medical device market entry in the United Mexican States is rooted in Article 4 of the Constitución Política de los Estados Unidos Mexicanos, which guarantees the human right to health protection, and Article 376 of the Ley General de Salud, as amended through 15 January 2026⁸. Under Article 376, medicinal products, medical devices, prostheses, orthoses, functional aids, diagnostic agents, dental inputs, surgical and healing materials, and hygienic products require an autonomous sanitary registration (Registro Sanitario) granted by the Secretaría de Salud through COFEPRIS in order to be manufactured, marketed, imported, or distributed within Mexican national territory⁸.

Article 262 of the Ley General de Salud defines the statutory scope of medical devices (insumos para la salud), encompassing medical equipment, prostheses, orthoses and functional aids, diagnostic agents, dental inputs, surgical and healing materials, and hygienic products⁸. The federal reform published in the Diario Oficial de la Federación on 15 January 2026 added Article 262 Bis. That article requires tecnovigilancia once a sanitary registration is granted: identification and evaluation of incidents and adverse incidents, and of associated risk factors, conforme a las disposiciones jurídicas aplicables — currently NOM-240-SSA1-2012, not a later NOM-240-SSA1-2025 (that text remains a project)⁸. A foreign authorization — an EU CE certificate, an FDA 510(k) clearance letter, an NMPA registration certificate, or a Japanese PMDA approval — does not connect a product to Mexico’s post-market network, does not satisfy Article 262 Bis, and does not grant legal market entry⁸.

In practice, Mexican customs and sanitary controls treat an active COFEPRIS registro number as the market-placement instrument for regulated devices. Presenting only an EU CE certificate, a US FDA 510(k) summary, or an ISO 13485 audit report does not substitute for that number on an import pedimento. Exact seizure, bonded-warehouse, or fine consequences depend on the Ley Aduanera file and the SAT/ANAM case. The operational point for a buyer is simpler: foreign certificates are dossier inputs, not the Mexican title⁸.

In administrative evaluation, foreign approvals serve strictly as regulatory reference inputs (documentos de referencia o antecedentes regulatorios). Under Mexico’s equivalence agreements and reliance frameworks, presenting an eligible foreign clearance enables COFEPRIS assessors to adopt an abbreviated technical review, recognizing the clinical safety and performance assessments already executed by a recognized authority¹. This expedited mechanism does not eliminate the administrative necessity of lodging a formal application, paying statutory federal rights fees, submitting Spanish-language labeling, and obtaining an official registration document (oficio de registro sanitario) issued by COFEPRIS¹. For labeling, NOM-137-SSA1-2008 remains the in-force sanitary-label NOM until NOM-137-SSA1-2025 — published 19 May 2026 — enters into force 360 calendar days later (about 14 May 2027)¹⁵.

This distinction is equally critical for international procurement standards such as World Health Organization (WHO) Prequalification. In global public health initiatives—such as donor-funded programs for voluntary medical male circumcision (VMMC)—a WHO Prequalification listing is a mandatory procurement threshold. However, under Mexican public health law, WHO prequalification is not an administrative marketing authorization. While Article 23 of the 18 July 2025 Lineamientos recognizes WHO prequalification for generic active pharmaceutical ingredients and drug products, Article 24 explicitly restricts medical device reliance to decisions rendered by member authorities of the IMDRF Management Committee². An international buyer holding a WHO-prequalified circumcision device must still obtain a COFEPRIS sanitary registration before commercializing the product in Mexico. To verify how foreign certificates and legal instruments function as supporting evidence, procurement teams should review how to verify the Certificate of Free Sale the Mexican abbreviated dossier still asks for, how to verify the 510(k) that may support 2010 option A without treating clearance as Mexican authorisation, how to verify the CE certificate that may support Option F without replacing COFEPRIS registration, and why WHO prequalification of a circumcision device is a VMMC tender gate, not a Mexican registro.

In addition, COFEPRIS enforces rigorous legal standards regarding the Certificate of Free Sale (Certificado de Libre Venta, CLV). The CLV must be issued directly by the sovereign health authority of the country of origin or reference country, certifying that the medical device is authorized and freely commercialized in that territory. For Chinese manufacturers, the CLV is issued by the competent provincial Medical Products Administration. When utilizing an EU CE certificate under Option F, the CLV must originate from the competent health authority of the European member state where the legal manufacturer or authorized representative is legally established. All CLV documents must be authenticated via Hague Apostille or Mexican consular legalization, and any discrepancy between the catalog models listed on the CLV and those declared in the Mexican application leads to immediate administrative rejection.

Which three instruments are actually live in 2026: 2010 FDA/Canada, 2012 Japan, and 18 July 2025 Option F — and did Transitory Fifth repeal the device agreements?

Following the publication of the Acuerdo por el que se emiten los Lineamientos generales para la aplicación de la vía regulatoria abreviada in the Diario Oficial de la Federación on 18 July 2025², international regulatory blogs and law firm summaries widely reported that Mexico had abolished its historical bilateral equivalence agreements in favor of a single unified reliance scheme. Multiple consulting firms advised clients that 'the 2010 FDA equivalence agreement is officially dead.' A detailed statutory review of the official guidance published by COFEPRIS demonstrates that this conclusion is legally and operationally incorrect.

The definitive administrative manual published by COFEPRIS—Guía de requisitos para el trámite de Registro Sanitario de Dispositivos Médicos mediante Acuerdos de Equivalencia y vía Regulatoria abreviada (file 1084062, official edition 12 June 2026)¹—clarifies that three distinct legal fast-track instruments remain active and operational across Form FF-COFEPRIS-01:

• Options A, B, and C (2010 US FDA and Health Canada Equivalence): Governed by the bilateral Acuerdo published in the DOF on 26 October 2010. Option A applies to devices cleared or approved by the US FDA (510(k) under section 510(k), PMA under section 515, or compliance with section 514 performance standards). Option B applies to medical devices manufactured in Canada holding a Class II, III, or IV Medical Device Licence (MDL) issued by Health Canada under the Medical Devices Regulations (SOR/98-282). Option C applies to medical devices manufactured outside Canada but authorized for sale in Canada under an active MDL¹.
• Options D and E (2012 Japan MHLW/PMDA Equivalence): Governed by the bilateral Acuerdo published in the DOF on 25 January 2012. Option D applies to devices manufactured in Japan holding premarket certification (Ninsho) issued by a Registered Certification Body or premarket approval (Shonin) granted by the Ministry of Health, Labour and Welfare (MHLW). Option E applies to devices manufactured outside Japan by an accredited/registered foreign manufacturer holding Japanese Ninsho or Shonin authorization¹.
• Option F (18 July 2025 Abbreviated Regulatory Pathway / Reliance): Governed by the multilateral Lineamientos published on 18 July 2025. Transitorio PRIMERO brings those lineamientos into force 30 business days after publication — not a separately enacted 1 September 2025 statute. Option F allows applicants to base the Mexican submission on a marketing authorization issued by a regulatory authority belonging to the IMDRF Management Committee², ³.

The legal mechanism explaining why the 2010 and 2012 device agreements remain operational is Transitorio Quinto of the 18 July 2025 decree, read together with the 12 June 2026 COFEPRIS guide², ¹. Quinto leaves without effect a listed set of prior agreements: the 28 January 2020 medicines agreement and its 22 June 2021 modification; the 29 March 2019 WHO-prequalification medicines agreement; the 22 November 2012 and 5 October 2012 medicines agreements with EMA, Swissmedic, FDA, Health Canada and TGA; and the 11 June 2025 unified agreement that had cited RIS Articles 167, 170, 177, 177 Bis 2, 179 and 180. Quinto therefore does mention RIS 179 and 180 — but only as the 11 June 2025 instrument it repeals. It does not name the 26 October 2010 FDA/Canada device agreement or the 25 January 2012 Japan device agreement. Those two bilateral device instruments remain the legal basis the June 2026 guide still prints as Options A–E.

Under administrative law principles set forth in the Código Civil Federal (Article 9) and the Ley Federal de Procedimiento Administrativo, an administrative rule or decree remains in full force until it is expressly repealed by a subsequent act of equal or higher legal hierarchy, or when a new statute contains provisions that are fundamentally incompatible with the previous decree. Because the 18 July 2025 Lineamientos established a generalized reliance framework without repealing the specialized bilateral agreements for medical devices, the bilateral instruments continue to operate as specialized fast-track options (lex specialis). In practice, COFEPRIS assessors at the Centro Integral de Servicios (CIS) continue to accept applications under Options A through E, processing them under their established document checklists.

This distinction is essential for commercial strategy. If an overseas manufacturer produces a surgical stapler with an active US FDA 510(k) clearance, the Mexican titular can elect to file under Option A (2010 Equivalence) or under Option F (2025 Abbreviated Pathway)¹. Both pathways utilize homoclave COFEPRIS-04-050 and require comparable administrative dossiers, but understanding their separate legal lineage prevents regulatory confusion during technical evaluation. For sister country-entry comparisons, see why a Health Canada MDL is a 2010-equivalence or Option F input, not a COFEPRIS oficio and why a Japanese MAH licence is an Option F or 2012-equivalence input, not a Mexican sanitary registration.

What does Article 24 actually recognize: IMDRF Management Committee country decisions versus MDSAP full members for GMP certificates only?

Article 24 of the 18 July 2025 Lineamientos establishes the eligibility criteria for medical device reliance in Mexico². In international regulatory consulting, Article 24 is frequently cited as granting blanket recognition to any device holding an MDSAP audit certificate. A rigorous reading of Article 24 reveals a strict statutory bifurcation between product authorization reliance and manufacturing quality reliance:

• Article 24, Fraction I (product-authorization reliance): the official Spanish text reads: «Para dispositivos médicos, la COFEPRIS reconoce las decisiones de las Autoridades Reguladoras de Referencia de: I. Países miembros del Management Committee del International Medical Device Regulators Forum (IMDRF)»². In 2026 that committee has twelve members: Australia (TGA), Brazil (ANVISA), Canada (Health Canada), China (NMPA), the European Union (European Commission DG SANTE), Japan (MHLW/PMDA), the Russian Federation (Ministry of Health), Singapore (HSA, 2026 IMDRF Chair), South Korea (MFDS), Switzerland (Swissmedic), the United Kingdom (MHRA), and the United States (FDA)⁷. A valid product clearance from any of those member authorities can support Option F evaluation. The EU is a member jurisdiction, not a twelfth sovereign state.
• Article 24, Fraction II (MDSAP limited to GMP certificates): «II. Miembros plenos del Programa de Auditoría Única de Dispositivos Médicos (MDSAP por sus siglas en inglés), para Certificados de Buenas Prácticas de Fabricación.»² The 21 July 2025 COFEPRIS press release restates the same split: IMDRF Management Committee decisions for devices, MDSAP full members for GMP certificates⁴.

Fraction II is a GMP-certificate rule, not a product-authorization passport. An MDSAP audit certificate issued by an authorized Auditing Organization documents that the manufacturing facility was audited against ISO 13485 plus the MDSAP participating authorities’ QMS requirements. The five full MDSAP participants remain Australia TGA, Brazil ANVISA, Health Canada, Japan MHLW/PMDA, and US FDA. Official observers commonly include the EU and UK MHRA; affiliate members commonly include Korea MFDS and Singapore HSA — statuses that are not product-authorization eligibility under Fraction I. Submitting an MDSAP certificate can support the BPF/GMP cell; it does not replace a Fraction I product decision. An applicant presenting only MDSAP plus ISO 13485, without an IMDRF Management Committee product authorization, is still on the ordinary technical file¹, ⁴.

To understand the operational mechanics of Fraction I, consider the documentation required from each of the twelve IMDRF member jurisdictions. For an Australian device, the applicant must present the official Certificate of Inclusion in the Australian Register of Therapeutic Goods (ARTG) issued by the TGA. For a Brazilian device, the proof consists of the definitive Registro or Notificação published in the Diário Oficial da União (DOU) by ANVISA. For a Canadian device, it is the active Medical Device Licence (MDL) issued by Health Canada. For a Chinese device, the applicant must submit the formal Medical Device Registration Certificate (医疗器械注册证) issued by the NMPA, accompanied by the approved Product Technical Requirements (PTR). For a European device, the submission requires the Certificate of Conformity issued by a notified body under Regulation (EU) 2017/745 (MDR) alongside the EU Declaration of Conformity. For Japan, it is the Shonin approval or Ninsho certification. For Russia, Singapore, Korea and Switzerland, use the authorization document issued by that Management Committee member as mapped in Table 2. For the United Kingdom, it is the MHRA device registration confirmation. For the United States, it is the formal 510(k) clearance letter, PMA approval order, or De Novo grant notice from the FDA.

Failure to recognize this statutory boundary represents one of the most common causes of dossier rejections at COFEPRIS. Foreign manufacturers that attempt to lodge an Option F application relying solely on an MDSAP certificate and an ISO 13485 declaration without an accompanying product approval from an IMDRF Management Committee member authority receive immediate official deficiency notices (prevenciones). To understand how quality system certificates interface with product authorization requirements across jurisdictions, see why an ISO 13485 or MDSAP certificate is GMP evidence, not Mexican product authorisation, why an HSA SMDR listing is not a COFEPRIS sanitary registration, why an Australian ARTG inclusion is an Option F input, not a COFEPRIS oficio, and why a UKCA certificate or UK Responsible Person is not a Mexican sanitary registration.

Who may apply — overseas manufacturer, Mexican titular, or consultancy 'MRH' — and what must already exist in Mexico?

A non-Mexican manufacturing entity cannot directly submit a registration dossier to COFEPRIS, nor can it hold a Mexican sanitary registration in its own foreign corporate name. Under Article 376 of the Ley General de Salud and Article 82 of the Reglamento de Insumos para la Salud, the applicant and legal owner of a Registro Sanitario must be an entity legally incorporated and domiciled within Mexican national territory, known as the Titular del Registro Sanitario⁸. The legal representative acting on behalf of the titular must reside in Mexico and hold an official power of attorney (Poder Notarial) granted by the foreign legal manufacturer, legalized via Hague Apostille or consular authentication¹.

Before lodging any medical device application under homoclave COFEPRIS-04-050 or COFEPRIS-04-001, the Mexican titular must have established three mandatory regulatory operational pillars:

• Aviso de Funcionamiento (Operating Notice): The Mexican corporate entity must possess an active Aviso de Funcionamiento formally lodged with COFEPRIS authorizing the commercialization, storage, and importation of medical devices. The facility must comply with Good Distribution Practices, including climate-controlled warehousing, segregated quarantine areas for non-conforming goods, calibrated temperature/humidity monitors, and documented Standard Operating Procedures (PNOs).
• Responsable Sanitario (Sanitary Responsible Officer): The titular must formally designate a qualified healthcare professional (typically a licensed pharmacist, chemist, or biomedical engineer holding an official cédula profesional) registered before COFEPRIS via an Aviso de Responsable Sanitario. The Responsable Sanitario is legally accountable for batch traceability, product release verification, and compliance with Mexican sanitary norms.
• Technovigilance Unit (Unidad de Tecnovigilancia): Under the in-force NOM-240-SSA1-2012, the registration titular (or Mexican legal representative) is responsible for implementing tecnovigilancia, including a designated unit and reporting to the Centro Nacional de Farmacovigilancia (CNFV) as that NOM provides. Article 262 Bis now states the obligation at statute level but does not rename CNFV or enact a 2025 NOM. A PROY-NOM-240 update has been consulted; it is not the in-force standard.

When establishing a commercial structure in Mexico, foreign medical device manufacturers face three distinct operational models, each carrying profound commercial implications:

• Wholly Owned Mexican Subsidiary: The foreign manufacturer incorporates its own Mexican operating company (e.g. Sociedad Anónima de Capital Variable, S.A. de C.V.), establishes a local warehouse or contracts a third-party logistics (3PL) provider, and employs a local Responsable Sanitario. This model provides complete operational autonomy and ownership of the registrations, but incurs substantial overhead and ongoing administrative expense.
• Independent Regulatory Holding Company (Mexican Registration Holder / MRH): The foreign manufacturer contracts an independent regulatory consulting firm or specialized holding entity in Mexico to act as the titular. The MRH holds the registration on behalf of the manufacturer and issues commercial import permits to multiple non-exclusive distributors. This model prevents any single commercial distributor from monopolizing product importation while allowing the manufacturer to scale its distributor network.
• Commercial Distributor as Titular: The foreign manufacturer authorizes its local commercial distributor to act as the registration titular. While this model eliminates upfront regulatory retainer fees, it carries severe commercial risks. Under Mexican administrative law, the titular controls all importation, customs clearances, and regulatory amendments. If the commercial relationship deteriorates, transferring the registration to another distributor (Cesión de Derechos) requires the voluntary, notarized consent of the existing titular and an administrative amendment approval from COFEPRIS. If the distributor refuses to cooperate, the foreign manufacturer cannot import its products through other channels and may be forced to cancel the registration and restart the filing process from scratch. For corporate structural analysis, see who is the legal manufacturer whose Mexican titular and legal representative must file the registro.

Essential Clauses in Mexican Regulatory Representation Contracts

When an overseas medical device manufacturer engages an independent Mexican holding entity or authorizes a commercial distributor to hold its sanitary registrations, the underlying representation agreement (Contrato de Representación Regulatoria) must incorporate robust protective clauses to safeguard international commercial assets. Without specific contractual protections, foreign manufacturers risk losing commercial control over their Mexican market access:

• 1. Mandatory Registration Transfer Commitment (Compromiso de Cesión de Derechos): The contract must explicitly stipulate that the sanitary registration is held in trust for the exclusive benefit of the foreign manufacturer. The Mexican titular must be legally bound to execute a formal, notarized registration transfer (Cesión de Derechos) before COFEPRIS within thirty calendar days of receiving written notification from the manufacturer, without levying exit penalties or obstructing the transfer.
• 2. Multi-Distributor Import Authorization Rights: The agreement must obligate the titular to issue unconditioned import authorization letters (Cartas de Autorización de Importación) to any commercial distributors, hospital procurement consortia, or 3PL logistics partners designated in writing by the manufacturer, preventing an exclusive commercial distributor from creating an unauthorized import monopoly.
• 3. Intellectual Property & Technical Dossier Ownership: The representation contract must expressly establish that all engineering dossiers, preclinical testing reports, clinical data, and registered commercial trademarks remain the exclusive intellectual property of the foreign manufacturer. The titular must be contractually barred from registering the manufacturer's brand names or domain names before the Mexican Institute of Industrial Property (Instituto Mexicano de la Propiedad Industrial, IMPI).
• 4. Operational Technovigilance Protocols: The representation contract should set information-exchange clocks between the manufacturer’s global quality team and the Mexican titular’s Unidad de Tecnovigilancia so the titular can meet NOM-240-SSA1-2012 notification duties. Those contract clocks are commercial terms, not a 48-hour rule printed in Article 262 Bis.
• 5. Independent Audit and Facility Access Rights: The foreign manufacturer must retain the contractual right to perform annual quality audits—either directly or through accredited third-party auditors—of the titular's warehousing infrastructure, standard operating procedures (PNOs), temperature monitoring records, and regulatory archive.

How does Mexico classify devices I-II-III under RIS Article 83, and why must you not import EU IIa, NMPA Class II or FDA product-code class as the Mexican class?

Medical device risk classification in Mexico is established by Article 83 of the Reglamento de Insumos para la Salud, supplemented by the classification criteria set forth in Appendix II of the Supplement for Medical Devices of the Mexican Pharmacopoeia (Farmacopea de los Estados Unidos Mexicanos, FEUM)⁹. COFEPRIS stratifies medical devices into three risk tiers based on their potential risk to human health, degree of invasiveness, and duration of contact with the body:

• Class I (Clase I): «Aquellos Insumos conocidos en la práctica médica y que su seguridad y eficacia están comprobadas y, generalmente, no se introducen al organismo»⁹. Typical illustrations include many non-invasive devices; the labelled intended use still has to be read against FEUM Appendix II.
• Class II (Clase II): «Aquellos Insumos conocidos en la práctica médica y que pueden tener variaciones en el material con el que están elaborados o en su concentración y, generalmente, se introducen al organismo permaneciendo menos de treinta días»⁹.
• Class III (Clase III): «Aquellos Insumos nuevos o recientemente aceptados en la práctica médica, o bien que se introducen al organismo y permanecen en él, por más de treinta días»⁹.

The classification system detailed in Appendix II of the FEUM Medical Device Supplement establishes twenty-two structured classification rules modeled after Global Harmonization Task Force (GHTF) principles. These rules evaluate four primary dimensions: (1) degree of invasiveness (non-invasive, invasive via body orifices, surgically invasive); (2) duration of contact (transient contact under 60 minutes, short-term contact up to 30 days, long-term contact exceeding 30 days); (3) anatomical exposure (contact with breached dermis, mucous membranes, central circulatory system, or central nervous system); and (4) active energy delivery or drug-combination characteristics.

A pervasive regulatory failure among foreign manufacturers is 'classification transposition'—assuming that because an item is categorized as Class II under China NMPA regulations, Class IIa under the European Union MDR, or Class II under US FDA product codes, it automatically maps to Class II in Mexico. Mexican classification is an autonomous legal determination governed strictly by the 22 classification rules in FEUM Appendix II. For instance, under FEUM Rule 8, any surgical device that is surgically invasive and intended to be absorbed by internal tissues over a period exceeding thirty days is classified as Class III in Mexico, even if foreign regulators cleared the device under a legacy Class II predicate. Sourcing teams must perform an independent Mexican classification review before preparing technical files. Compare how other national authorities evaluate surgical consumables in why an MFDS licence is not a Mexican class or registro, and why Class I aftercare pants must not inherit a surgical-device class.

What do Ley Federal de Derechos Article 195-A-III and Article 38 print for fees and the abbreviated clock, versus RIS standard 30/35/60-day clocks and consultancy USD/10-year cards?

Official government user fees for medical device registrations are codified in the Ley Federal de Derechos (LFD). Under Article 195-A, Section III of the LFD compilation published by the Cámara de Diputados, official registration cuotas for medical equipment, prostheses, surgical and healing materials, and related devices are levied in Mexican Pesos (MXN) according to statutory risk class¹⁰:

• Class I Registration Fee (LFD Art. 195-A-III-a): $16,498.70 MXN.
• Class II Registration Fee (LFD Art. 195-A-III-b): $24,198.08 MXN.
• Class III Registration Fee (LFD Art. 195-A-III-c): $30,797.57 MXN.

Online marketing literature published by regulatory consultancies frequently advertises USD-denominated fee schedules, such as ‘approximately $700 USD for Class I’ or ‘$1,027 USD for Class II.’ Those estimates are not the statutory cells. Fees must be calculated and paid to the Mexican Treasury (Tesorería de la Federación) via the SAT e5cinco scheme in Mexican Pesos at the exact statutory rate in force on the date of submission¹⁰. The stamped banking receipt belongs in the administrative-legal section of the physical dossier. Use the clave de referencia printed on the current e5cinco voucher for that homoclave and class.

Statutory evaluation clocks also diverge between instruments. Under Article 38 of the 18 July 2025 Lineamientos, COFEPRIS has a maximum of thirty business days (30 días hábiles) for medical-device applications under the abbreviated pathway (Option F)². Under ordinary evaluation, RIS Article 83 prints thirty days for Class I (afirmativa ficta if unanswered), thirty-five days for Class II, and sixty days for Class III — as días, not días hábiles⁹.

A thirty-business-day Article 38 clock is a maximum for the abbreviated pathway, not a promise of six calendar weeks to an oficio. If COFEPRIS issues a prevención, the file is not moving on the original clock until the response is complete; abandonment follows a failure to answer. Consultancy pages often quote 3–6 months for abbreviated files and 6–12 months for ordinary files as observed practice. Those ranges are not printed in RIS Article 83 or Article 38 and should not be treated as official cuotas.

Beyond official government rights fees, international manufacturers must budget associated procedural costs: certified translation, apostille or consular legalization, Mexican titular retainers where the factory has no subsidiary, and technovigilance administration. Those market figures in Table 4 are labelled estimates, not LFD cells. On validity, Ley General de Salud Article 376 still prints a five-year initial vigencia and, after the 15 January 2026 reform, allows the registro to be prorrogado for 10-year periods en los términos que establezcan las disposiciones reglamentarias⁸. A first-issue certificate is not automatically ten years. Renewal timing follows those reglamentary provisions rather than a consultancy calendar-day window.

Can homoclave COFEPRIS-04-050 be filed digitally, and why does a USB stick not replace the physical expediente?

In the Mexican federal administrative registry (Catálogo Nacional de Trámites y Servicios), equivalence and abbreviated medical device filings are assigned homoclave COFEPRIS-04-050 (Solicitud de Registro Sanitario de Dispositivos Médicos por equivalencia / vía abreviada)¹¹. Following the rollout of digital platforms like DIGIPRIS, many international companies assume that homoclave 04-050 can be submitted electronically online.

The official COFEPRIS guide published on 12 June 2026 states, in Important Note 1: «La homoclave 04-050 actualmente no se encuentra habilitada para su presentación en modalidad digital, por lo que la entrega de documentación únicamente mediante un dispositivo de almacenamiento electrónico (USB) no sustituye la presentación física de la solicitud ni de los documentos que integran el expediente.»¹ Applications under Options A–F must therefore still be presented as a physical expediente until a digital platform is enabled. The guide does not name DIGIPRIS in that sentence.

A USB stick or CD-ROM of searchable PDFs may accompany the binder; it does not replace the physical solicitud and expediente¹. Guide Note 5 (RIS Article 153) allows technical documents in Spanish or English; any other language needs a simple Spanish translation, and legal documents need a perito traductor. Certificates of Free Sale, manufacturing licences and powers of attorney still need Apostille or consular legalization unless the guide’s electronic-verification exception applies.

Admission at the ventanilla follows the document groups in Article 31 of the 18 July 2025 lineamientos and the June 2026 guide checklists², ¹:

• Administrative-legal section (Article 31 I): personality/RUPA; rights payment voucher; Spanish label project; IFU/manual as applicable; GMP certificate or equivalent; Certificate of Free Sale or equivalent from the reference agency; the ARR product authorization; and a carta de representación when Article 161/182 requires it.
• Technical section (Article 31 II): device description; components and formulation; manufacturing summary; the conformity evidence presented to the ARR; primary/secondary packaging; clinical evaluation; risk analysis; finished-product certificate; and a tecnovigilancia report. The June 2026 guide restates these cells per option (A–F).
• Spanish labeling: until about 14 May 2027, build the project to NOM-137-SSA1-2008 and track NOM-137-SSA1-2025 so artwork does not miss the incoming rule¹⁵. See why an EU REP symbol clock is not the Mexican Spanish-label file.
• Physical presentation: legible, paginated paper as the June 2026 guide requires. A suggested editable draft oficio (guide Note 7) is a convenience, not a substitute for the issued certificate.

What the 20 August 2026 visor can and cannot prove when you try to verify a listing

On 20 August 2026, COFEPRIS issued Comunicado de Prensa 21/2026, announcing the public deployment of the Visor de Registros Sanitarios de Dispositivos Médicos (registros.cofepris.gob.mx/BRSDM)⁵, ⁶. Designed as a public transparency search portal, the visor enables healthcare providers, importers, and procurement officers to query active sanitary registrations by commercial brand name, generic denomination, registration number, or titular company.

While the launch of the visor represents a commendable modernization initiative, international distributors and hospital procurement committees must recognize four strict legal boundaries governing its evidentiary weight:

• A Visor Hit is Not the Legal Title (Oficio): Under Mexican customs regulations and public tender procurement rules (IMSS, ISSSTE, IMSS-Bienestar), a printed search result from the visor does not constitute legal proof of registration. Customs dispatch requires the official, stamped paper certificate (Oficio de Registro Sanitario) issued by the Dirección Ejecutiva de Autorizaciones Sanitarias, or a formal certified copy accompanied by the authorized Spanish labeling project⁵.
• The Visor Does Not Print Risk Class or Full Specifications: The public consultation interface displays high-level metadata: registration number, titular name, product denomination, and expiration date. It does not publish the device's statutory risk classification (Class I, II, or III), approved bill of materials, detailed indications, or specific SKU model variants authorized in the annexes.
• Stage-One Rollout is Incomplete: In Comunicado 21/2026, COFEPRIS expressly highlighted that the visor is being implemented in two stages and undergoes continuous data updates. During Stage One, COFEPRIS established an observation window for registration holders (titulares) to submit corrections, reconciliations, or missing data to digipris@cofepris.gob.mx. Consequently, the absence of a record in the visor during this rollout phase does not establish that a device is unregistered or illegal⁵, ¹².
• Third-Party Registrations Do Not Authorize Your Consumable: Locating a generic registration row for a product category (e.g. 'catéter vascular' or 'anillo quirúrgico') held by an unrelated Mexican company does not authorize an importer to clear a different manufacturer's goods. Every imported lot must strictly correspond to the legal manufacturer, manufacturing plant, and product models explicitly authorized in the titular's oficio¹.

For a forensic analysis of how public register extracts can mislead buyers into false assumptions of product authorization, see why a public COFEPRIS issuance-list or visor hit is not proof that a named fiber is authorised for your SKU.

Customs Clearance and Hospital Tender Verification Protocols

The visor’s limits show up at customs dispatch and in public tenders for IMSS, ISSSTE and IMSS-Bienestar. Tender bases typically ask for a certified copy of the oficio and the authorized Spanish labeling project (proyecto de marbete), not a visor screenshot, a CE certificate, or a 510(k) summary. Whether a missing oficio is scored as technical disqualification depends on that tender’s bases.

At ports of entry, customs brokers compare the commercial invoice and packing list with the catalog codes and presentations in the registration annexes. An unregistered SKU variant, pack count, or sterile-barrier change is a modification file, not a visor lookup. Current administrative and technical modification homoclaves for devices are the 2022-series codes. Do not ship the variant until the oficio annex matches the lot.

Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber versus Class I aftercare pants, and why NOVACURE is out of scope

To demonstrate the practical execution of the 2026 Mexican regulatory framework, consider three distinct sterile consumable scenarios manufactured by an international facility (Weihai Medison Medical Equipment Co., Ltd. / VEMERIX):

Worked Example 1: CE-Marked Disposable Circumcision Device

The VEMERIX Disposable Circumcision Device is an ethylene oxide (EO) sterilized self-detaching ring for adult and pediatric circumcision, supplied sterile in individual blister packs. The public product page records China NMPA Class II registration (Lu Mech Reg. 20172020238) and CE yes; it does not print a 510(k) number or name the CE directive versus MDR certificate¹³.

• Pathway Selection: Because the device lacks an FDA 510(k), Option A under the 2010 Equivalence Agreement is legally closed. However, because the European Union is a full member of the IMDRF Management Committee, the Mexican titular can apply under Option F (Abbreviated Pathway / Reliance) pursuant to Article 24.I of the 18 July 2025 Lineamientos².
• Evidence assembly: Form FF-COFEPRIS-01 selecting Option F; authenticated CE certificate and declaration of conformity as actually issued; apostilled Certificate of Free Sale from the relevant EU competent authority; ISO 13485 certificate; Spanish labeling project; Mexican titular appointment; and the LFD cuota for the Mexican class COFEPRIS assigns — $24,198.08 MXN only if that class is II¹, ¹⁰.
• Review Clock: The application is subject to the 30-business-day evaluation clock under Article 38 of the 2025 lineamientos².

A critical technical nuance during dossier review involves the scope statement on the foreign manufacturer's ISO 13485:2016 certificate. COFEPRIS assessors cross-reference the certificate's certified scope against the Mexican application. The certified scope must explicitly encompass the design, development, and cleanroom manufacture of sterile urological surgical instruments or circumcision devices. If the quality certificate lists only a broad generic category—such as 'manufacture of plastic components'—COFEPRIS will halt evaluation and issue an official deficiency request (prevención), requiring an amended certificate or formal explanatory letter from the accredited certification body.

Worked Example 2: Disposable Medical Laser Fiber (NMPA Registered, No CE)

The VEMERIX Disposable Medical Laser Fiber is a sterile, single-use optical fiber (radial and bare tip configurations) designed for endovenous laser ablation of varicose veins¹⁴. The fiber holds an active China NMPA Class II registration certificate (certificate 20192010517). The manufacturer does not claim a European CE mark for this fiber¹⁴.

• Pathway Selection: Options A–C (FDA/Canada) and Options D–E (Japan) are inapplicable. However, China's NMPA is a recognized member of the IMDRF Management Committee⁷. Therefore, the Mexican titular can lodge the application under Option F using the Chinese NMPA registration certificate as the reference authorization under Article 24.I².
• Boundary Discipline on Capital Consoles: Sourcing teams must avoid a critical regulatory error: attempting to 'borrow' CE certification from a surgical laser generator. In vascular surgery workflows, the single-use laser fiber is frequently operated in conjunction with a diode laser console (such as the NOVACURE 1470 nm console). The NOVACURE console is a partner-supplied capital system and is completely independent of the disposable fiber. Under Mexican law, the capital console and the disposable fiber require separate, independent sanitary registrations. Distributors must never attempt to represent an NMPA-only fiber as CE-marked by citing the partner-supplied generator¹⁴. See why an NMPA-registered laser fiber without a Medison CE claim still needs its own Mexican file and why an NMPA certificate may support Option F and still does not place the device in Mexico.

The fiber technical file still has to show the optical and mechanical performance the labelled endovenous use requires. Use the laboratory’s actual methods and limits from the current bench reports; the public product page does not print connector-pull or transmission acceptance numbers.

Worked Example 3: Circumcision Care Protective Pants (Class I / Exemption Evaluation)

Circum-CARE post-operative protective pants are a purpose-built external garment. The public product page records a China Class I filing (Lu Wei Mech Filing 20190014) and describes wound-margin protection — so Mexican class and exemption cannot be copied from the surgical ring, and cannot be assumed to be ‘intact-skin only.’

• Classification trap: grouping aftercare garments into the same registro as the invasive circumcision clamp is the usual error. RIS Article 83 still has to be applied to the pants’ labelled use, independently of the ring⁹.
• Exemption screening: LGS Article 376 exempts devices the authority has listed as low-risk and not requiring registration. That list is the DOF agreement of 7 July 2025 (Annexes One, Two and Three) — not Article 376 Bis, which is the unique-key rule for medicines⁸. If the labelled SKU is on Annex Two, sanitary registration and an import permit are not required, but GMP and tecnovigilancia duties still apply. If it is on Annex One, a low-risk registro is still required. Do not declare exemption from the product nickname.

When importing Class I or exempt aftercare garments, the Mexican importer must ensure that retail packaging adheres to general commercial and sanitary labeling norms in the Spanish language. Under NOM-050-SCFI-2004, the packaging must clearly state the commercial denomination, country of origin, importer corporate name and fiscal address (RFC), textile material composition, washing and handling instructions, and a statement that the item is a non-sterile external protective garment.

Distributor checklist, apostille/CLV pack, red flags, and the documents to request before the first Mexican shipment

To ensure compliance with COFEPRIS standards and protect international investments, medical device distributors and procurement teams should execute the following structured 10-step due diligence workflow before authorizing production or commercial shipment:

1. Independent Classification Determination: Classify each SKU under RIS Article 83 and FEUM Supplement Appendix II based on intended clinical use and tissue contact duration, confirming Class I, II, or III status independently of foreign classifications.
2. Exemption verification: Screen the labelled SKU against the 7 July 2025 DOF annexes under LGS Article 376, not Article 376 Bis.
3. Pathway Selection: Determine whether the product qualifies for the 2010 Equivalence Agreement (Options A–C; US FDA/Health Canada), the 2012 Agreement (Options D–E; Japan MHLW/PMDA), the 18 July 2025 Abbreviated Pathway (Option F; IMDRF MC country approval), or Standard Evaluation.
4. Mexican Legal Representation Agreement: Formalize the representation contract with an authorized Mexican entity holding an active Aviso de Funcionamiento and designated Responsable Sanitario, executing a notarized Power of Attorney (Poder Notarial).
5. Certificate of Free Sale (CLV / CFS) Pack: Procure the official Certificate of Free Sale issued by the reference competent authority, verifying that the manufacturer name, manufacturing facility address, and exact commercial models match the Mexican application, bearing a valid Apostille or consular legalization.
6. Quality System & GMP Evidence: Secure an authenticated ISO 13485:2016 certificate covering the manufacturing plant. If utilizing MDSAP under Article 24.II, verify that the audit report is issued by an authorized auditing organization recognizing a full MDSAP member authority.
7. Technical Dossier & Testing Reports: Compile preclinical testing reports (biocompatibility per ISO 10993, sterilization validation per ISO 11135 or ISO 11137, accelerated aging/shelf life, packaging integrity per ISO 11607, and bench performance testing).
8. Spanish labeling artwork: Author draft Spanish labels and IFU to the in-force NOM-137 (2008 until the 2025 NOM’s May 2027 entry into force), including warnings, batch coding, sterilization method, and placeholders for the Mexican registro number and titular address¹⁵.
9. Official Cuota Payment: Calculate official user fees under Ley Federal de Derechos Article 195-A-III and pay via the SAT e5cinco tax receipt mechanism in Mexican Pesos.
10. Physical Expediente Lodgement & Prevenires Monitoring: Submit the bound, sequentially paginated physical dossier for homoclave COFEPRIS-04-050 at the CIS window, monitor the evaluation clock, and promptly address any official requests for clarification (prevenciones) within the statutory window.

Following customs release at Mexican ports of entry, commercial shipments must be transported under controlled conditions directly into the authorized warehouse facility of the Mexican titular or contracted 3PL logistics provider. The titular's Responsable Sanitario must execute a formal incoming inspection protocol, verifying sterile barrier packaging integrity, lot number consistency against the foreign Certificate of Analysis (CoA), and complete adherence to authorized the in-force NOM-137 Spanish labeling. Every received commercial lot must be recorded in the facility's official inventory control log (Registro de Entradas y Salidas), establishing batch-level traceability from the overseas cleanroom to the end-user hospital. Hospital clinical engineering teams and institutional procurement committees (such as IMSS CEYE - Central de Equipos y Esterilización) routinely audit these release records before accepting surgical consumables into operating theaters.

Critical Red Flags in Mexican Device Procurement

• Red Flag 1: 'CE mark or FDA 510(k) clears Mexican customs directly.' Reject immediately. Article 376 of the Ley General de Salud mandates an independent Mexican Registro Sanitario for non-exempt devices.
• Red Flag 2: 'MDSAP replaces product registration.' Reject immediately. Article 24.II of the 18 July 2025 Lineamientos restricts MDSAP recognition strictly to Good Manufacturing Practice (GMP) validation, not product authorization.
• Red Flag 3: 'We filed the application online via email or USB.' Reject immediately. The 12 June 2026 COFEPRIS guide states homoclave 04-050 is not enabled for digital filing; submissions must be physical paper expedientes.
• Red Flag 4: ‘Our first-issue registration is valid for 10 years.’ Audit immediately. LGS Article 376 still prints a five-year initial term; 10-year periods apply to prórroga in the terms of the reglamentary provisions, not to an automatic first licence.
• Red Flag 5: 'We saw the product on the 2026 online visor, so no certificate is needed.' Reject immediately. The public visor is an initial consultation viewer; customs clearance and tenders require the official, stamped Oficio de Registro Sanitario.

Anatomy of a Compliant Technical Dossier for COFEPRIS-04-050

When assembling the technical section of a COFEPRIS-04-050 file, foreign manufacturers and Mexican titulars still have to cover the Article 31 II modules. Gaps in those modules are a common reason for prevenciones; that is an operational observation, not a COFEPRIS ranking:

• 1. Biological Safety & Biocompatibility (ISO 10993 Series): For Class II sterile consumables contacting mucous membranes or breached tissues (such as disposable circumcision devices) or the vascular system (such as endovenous laser fibers), the technical dossier must include full biocompatibility test reports executed by an accredited laboratory. In accordance with ISO 10993-1:2018, the mandatory evaluation battery comprises: (a) in vitro cytotoxicity (ISO 10993-5); (b) intracutaneous reactivity and skin sensitization (ISO 10993-10); (c) acute systemic toxicity (ISO 10993-11); (d) material-mediated pyrogenicity (ISO 10993-11); and (e) hemocompatibility (ISO 10993-4) for blood-contacting optical fibers. Summaries or supplier declarations are rejected; COFEPRIS requires complete, signed test reports.
• 2. Sterilization Cycle Validation (ISO 11135 / ISO 11137): For ethylene oxide (EO) sterilized consumables, the applicant must demonstrate achieving a Sterility Assurance Level (SAL) of 10^-6 through fractional and half-cycle overkill validation protocols using biological indicators (Bacillus atrophaeus). Furthermore, the dossier must include testing of ethylene oxide and ethylene chlorohydrin residual limits in strict compliance with ISO 10993-7. For limited exposure devices (contact under 24 hours), residual limits must not exceed 4.0 mg/device for ethylene oxide and 9.0 mg/device for ethylene chlorohydrin.
• 3. Sterile Barrier Packaging Integrity (ISO 11607-1 & ISO 11607-2): COFEPRIS assessors verify that the primary packaging maintains sterility throughout labeled shelf life. Dossiers must include: (a) seal tensile strength testing per ASTM F88; (b) dye penetration microbial integrity testing per ASTM F1929; and (c) internal pressure bubble emission testing per ASTM F2096. Packaging validation reports must encompass both initial post-sterilization lots and aged samples.
• 4. Real-Time and Accelerated Aging (ASTM F1980): To substantiate a commercial shelf life (e.g. 3 years or 5 years), the manufacturer must provide accelerated aging protocol reports based on the Arrhenius reaction rate model using a conservative aging factor (Q10 = 2.0 at 55°C). The submission must include a formal written commitment from the manufacturer confirming that real-time aging stability protocols are concurrently underway under ambient warehouse conditions (25°C ± 2°C / 60% RH ± 5% RH).
• 5. Mechanical and functional bench performance: Quantitative reports that match the labelled clinical use. For circumcision rings, clamping-force retention and release reliability. For endovenous fibers, connector retention, optical transmission at the labelled wavelength, and distal-tip integrity — using the laboratory’s actual methods and limits.
• 6. Risk-management file (ISO 14971): A risk-analysis summary covering design and process FMEA, clinical-use mitigations, and a signed risk-benefit conclusion. Cite the edition actually used in the file.

Beyond premarket filing, the titular remains subject to sanitary surveillance and to Article 262 Bis tecnovigilancia. Unannounced verification visits and record checks are ordinary COFEPRIS tools; keep the foreign technical file and the Mexican archive aligned as a condition of remaining on the market, not as a one-time approval event⁸.

Where VEMERIX fits — and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. Public pages record ISO 13485 quality systems, NMPA Class II registrations on the circumcision ring (Lu Mech Reg. 20172020238, CE yes, EO, individual blister) and the disposable medical laser fiber (Lu Mech Reg. 20192010517, no Medison CE claim), and a China Class I filing on Circum-CARE pants¹³, ¹⁴. Those facts are not a Mexican class, a Mexican registro, or an EU MDR certificate number.

For distributors and OEM partners evaluating Mexico, VEMERIX can support an independent titular’s file-readiness review. That is a document request, not a claim that VEMERIX already holds Mexican registrations or acts as titular:

• Current technical-file summaries (biocompatibility, sterilization validation, packaging integrity, and bench reports as they actually exist for the SKU).
• Quality-system certificates and, where issued, Certificates of Free Sale — apostille status to be confirmed on the current originals, not assumed.
• Spanish-language specifications and draft labeling elements to help a Mexican titular build the in-force NOM-137 project.
• OEM/ODM discussion where a Mexican company would put its own name on the label and become the legal manufacturer of record.

VEMERIX does not act as a Mexican Registration Holder, does not sell regulatory proxy services, and does not claim a Mexican registro for these SKUs. Medison manufactures disposable surgical consumables; the partner-supplied NOVACURE diode laser console used alongside the vascular fiber is an independent capital system and is not offered here as a Medison-manufactured capital example. Due diligence begins with the distributor’s Mexican titular structure, an independent RIS Article 83 reading, and physical lodgement under homoclave COFEPRIS-04-050. Request the current pack via VEMERIX Quality or VEMERIX Contact.

Frequently Asked Questions

Do I still need COFEPRIS registration if my device already has CE, FDA 510(k) or NMPA?

Yes. Under Article 376 of the Ley General de Salud, every medical device marketed in Mexico must hold an official Registro Sanitario issued by COFEPRIS. Foreign approvals from the EU, US FDA, or China NMPA serve as eligible reference decisions to support expedited evaluation under the 2010 Equivalence Agreement or the 18 July 2025 Option F Abbreviated Pathway, but they do not replace the statutory Mexican registration certificate.

Was the 2010 FDA equivalence agreement repealed by the July 2025 abbreviated pathway?

No. Transitorio Quinto of the 18 July 2025 Lineamientos repeals listed medicine equivalence agreements and the 11 June 2025 unified agreement. It does not name the 26 October 2010 US FDA/Health Canada device agreement or the 25 January 2012 Japan device agreement. COFEPRIS’s 12 June 2026 operational guide continues to print Options A through E alongside Option F.

Does an MDSAP certificate let me skip Mexican product registration?

No. Article 24, Fraction II of the 18 July 2025 Lineamientos recognizes MDSAP full member certificates solely for the purpose of validating Good Manufacturing Practice (GMP / BPF) compliance. MDSAP is an audit of quality management systems; it is not a product approval. The device itself must still demonstrate premarket authorization from an IMDRF Management Committee authority under Fraction I or undergo standard evaluation.

Can the Chinese factory file COFEPRIS-04-050 by email or USB?

No. The applicant must be a legally constituted Mexican entity (Titular del Registro Sanitario) holding an active Aviso de Funcionamiento. Important Note 1 of the 12 June 2026 COFEPRIS guide states that homoclave COFEPRIS-04-050 is not enabled for digital presentation; USB-only delivery does not replace physical filing of the solicitud and expediente.

How much is the official 2026 registro fee for a Class II device?

Under Article 195-A, Section III-b of the Ley Federal de Derechos, the official government cuota for the sanitary registration of a Class II medical device is $24,198.08 MXN. Fees must be paid directly to the Mexican Treasury in Mexican Pesos via the SAT e5cinco tax payment mechanism.

Is the new visor the same thing as the oficio de registro sanitario?

No. The Visor de Registros Sanitarios launched on 20 August 2026 is an initial public consultation tool undergoing two-stage implementation and continuous reconciliation. Customs clearance and hospital procurement require the official, stamped paper certificate (Oficio de Registro Sanitario) issued by COFEPRIS.

Does WHO prequalification of a circumcision device authorise sales in Mexico?

No. WHO Prequalification is an international procurement standard used by global health agencies (such as PEPFAR); it is not an administrative marketing authorization under Mexican law. Furthermore, Article 24 of the 18 July 2025 Lineamientos restricts medical device reliance to IMDRF Management Committee member countries, whereas WHO prequalification is recognized only for generic pharmaceutical substances under Article 23.

Does VEMERIX already hold a Mexican registro sanitario for these SKUs?

VEMERIX manufactures sterile single-use devices under ISO 13485 quality systems and can provide current regulatory documentation (NMPA certificates, CE where the public product page records it, and CFS originals as issued) to support an independent distributor’s Mexican filing. VEMERIX does not act as a Mexican titular and does not sell regulatory holding services; distributors must establish local representation to lodge homoclave COFEPRIS-04-050.